Niacin Plus
90/100
This product looks safe
- Niacin: 250mg is 7.1× the Tolerable Upper Intake Level (35mg)
- 50% of ingredients have research evidence
C
Label Compliance Grade
Product Label
Have a supplement label? Find it here.
Upload a photo of any supplement label to search our database of 92,312 products.
Safety Alerts
⚠️ Niacin: 250mg is 7.1× the Tolerable Upper Intake Level (35mg)
Label Data
1 Vegetarian Tablet(s)
Serving Size
Other Combinations
Product Type
50%
Evidence Coverage
Supplement Facts — Evidence Check
250 mg
(1250% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 7.1× (UL: 35 mg)
📚 193 studies (Tier A: 5, B: 63)
30 mcg
(25% DV)
✅ Within RDA (0.9× RDA of 0.035 mg)
📚 197 studies (Tier A: 1, B: 55)
Policosanol
100 mg
Fo Ti
100 mg
Other Ingredients
Vegetable Wax
Tragacanth Gum
Stearic Acid
Vegetable Stearate
Silica
Label Claims — Verification
❓
All Other
All Other (97% of products)
Structure/Function (86% of products)
Nutrient (36% of products)
Target Groups
Adult (18 - 50 Years)
Gluten Free
Dairy Free
Sugar Free
Product Information
📋 Directions for Use
One to two tablets twice daily, as a dietary supplement.
⚠️ Warnings & Precautions
Warning: Not for use by children unless directed by health care practitioner.
🧪 Formulation Notes
Slow release Niacin
No corn, salt, yeast, gluten, milk & egg products, sugar, starch, or preservatives.
Additional Information
GMP Quality Assured Earth Friendly
% Daily Value
PR 1194
Product Details
UPC / SKU
7 68305 11946 8
DSLD Entry Date
2017-11-20
Product Type
Other Combinations
Form
Tablet or Pill
Brand
Highland Laboratories
DSLD ID
79943
Data Updated
2026-04-11
Research Evidence
241
Research Sources
55
Avg Quality Score
113
Meta Analysis
75
Systematic Review
32
Rct
11
Clinical Trial
3
Other
3
Regulatory Source
1
Cochrane Review
1
Narrative Review
1
Openfda Safety
A
Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
A
Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
A
A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
A
Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
B
Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Compare Similar Products
Rezistaf
LifeLink
100
Coenzymated B-3 25 mg
Source Naturals
100
Vitamin B Complex
Simply Supplements
100
Test X180 Boost
Force Factor
100
8-Hour Alert
MHP Maximum Human Performance
100